Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EuroNet Pediatric Nodular Lymphocyte-Predominant Hodgkin Lymphoma Study
2007-004092-19Phase 4Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Mar 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclophosphamide, vinblastine and prednisone in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and Hodgkin lymphoma (HL), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Event-free survival. Started Mar 2009; status: completed.
02
Drugs
cyclophosphamidevinblastineprednisone
03
Conditions
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2007-004092-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004092-19.